“8:30a ET 10/6/2022 - Globe Newswire
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
The microfluidics-based system accommodates scalable throughputs to address specific and evolving project needsGlobeNewswireOctober 06, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose -â?¯Unleashing tools to accelerate breakthroughs in human health(TM) - today announced the launch of the X9(TM) Real-Time PCR System, an innovative high-capacity genomics instrument offering superior efficiency.
X9 enables high data output with more than 9,000 individual nanoliter-volume reactions in a single run, ensuring cost-effective, comprehensive sample profiling with minimal operator contribution. Instead of using 96 plates worth of reagents, plastic and labor, X9 can reduce an experiment to a single integrated fluidic circuit (IFC) - a microfluidic chip. The X9 platform, powered by single-touchpoint operation, streamlines laboratory processes by integrating reaction setup into an automated workflow that generates up to 46,080 datapoints per 8-hour shift.
Agricultural genomics and clinical research labs require the flexibility to adapt to changing assay needs, so the ability to mix and match assays for quick and easy implementation with up to 96 targets is key. The X9 System integrates proven Standard BioTools(TM) proprietary microfluidics technology, which helps reduce experimental costs while accommodating relevant and popular applications and chemistries to meet the most demanding customer needs.
"We are committed to connecting the best solution to the needs of the customer, considering cost per sample or per run, throughput requirements, time to results and flexibility of content, among other factors," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Even with ongoing challenges of labor shortages and limited resources, labs are pressed to maintain the same level of output. X9 can help solve these issues by empowering these labs to work within their resources and do more with less.
"We are thrilled that this instrument is primed to support the researchers and core labs in agricultural genomics and clinical research communities, consistent with our sharpened commercial focus on high-value niche markets for specialized applications for which our platform is ideally suited. The system can support various real-time PCR studies, offering faster data output and better use of time."“
my posts are always theory and not financial advice
